Craig Mullen
Concepts (469)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Bone Marrow Transplantation | 15 | 1993 | 90 |
Why?
| Neutropenia | 13 | 1990 | 42 |
Why?
| Graft vs Leukemia Effect | 6 | 2002 | 4 |
Why?
| Hematopoietic Stem Cell Transplantation | 15 | 1993 | 49 |
Why?
| Fever | 10 | 1990 | 65 |
Why?
| Cancer Vaccines | 6 | 1999 | 21 |
Why?
| Graft vs Host Disease | 14 | 1999 | 29 |
Why?
| Neoplasms, Experimental | 9 | 1985 | 72 |
Why?
| Neoplasms | 17 | 1993 | 239 |
Why?
| Gene Therapy | 20 | 1992 | 89 |
Why?
| Transplantation, Homologous | 14 | 1998 | 94 |
Why?
| Graft vs Tumor Effect | 5 | 1999 | 4 |
Why?
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2008 | 8 |
Why?
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2002 | 33 |
Why?
| T-Lymphocytes | 12 | 1985 | 182 |
Why?
| Nucleoside Deaminases | 10 | 1992 | 10 |
Why?
| Minor Histocompatibility Antigens | 4 | 2000 | 5 |
Why?
| Ambulatory Care | 4 | 1999 | 106 |
Why?
| Bacterial Infections | 7 | 1990 | 88 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 6 | 1998 | 121 |
Why?
| T-Lymphocytes, Cytotoxic | 6 | 1997 | 52 |
Why?
| Mice | 32 | 1985 | 623 |
Why?
| Mice, Inbred C57BL | 16 | 1992 | 318 |
Why?
| Ciprofloxacin | 3 | 1998 | 11 |
Why?
| Lymphocyte Transfusion | 5 | 1993 | 13 |
Why?
| Anti-Bacterial Agents | 5 | 1999 | 195 |
Why?
| Thymidine Kinase | 6 | 1994 | 15 |
Why?
| Gene Transfer Techniques | 10 | 1993 | 59 |
Why?
| Animals | 41 | 1985 | 1031 |
Why?
| Graft Survival | 4 | 1998 | 74 |
Why?
| Fibrosarcoma | 6 | 1985 | 18 |
Why?
| Flucytosine | 6 | 1992 | 9 |
Why?
| B-Lymphocytes | 5 | 1995 | 134 |
Why?
| Female | 36 | 1986 | 1643 |
Why?
| Adenosine Deaminase | 6 | 1993 | 8 |
Why?
| Hydroxymethyl and Formyl Transferases | 3 | 1996 | 1 |
Why?
| Anti-Infective Agents | 3 | 1998 | 54 |
Why?
| Child | 21 | 1990 | 749 |
Why?
| Fusion Proteins, bcr-abl | 1 | 2008 | 10 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2008 | 15 |
Why?
| Cytotoxicity, Immunologic | 6 | 1985 | 54 |
Why?
| Genetic Vectors | 13 | 1992 | 139 |
Why?
| Retroviridae | 11 | 1993 | 36 |
Why?
| Tumor Markers, Biological | 1 | 2010 | 112 |
Why?
| H-Y Antigen | 1 | 2007 | 2 |
Why?
| T-Lymphocyte Subsets | 1 | 2008 | 70 |
Why?
| Neoplasm, Residual | 1 | 2007 | 19 |
Why?
| Immune Tolerance | 3 | 1985 | 72 |
Why?
| Humans | 57 | 1990 | 1856 |
Why?
| Ganciclovir | 5 | 1993 | 18 |
Why?
| Postanesthesia Nursing | 2 | 1995 | 2 |
Why?
| Transplantation Conditioning | 5 | 1998 | 23 |
Why?
| Certification | 2 | 1995 | 26 |
Why?
| Mice, Inbred C3H | 7 | 1986 | 86 |
Why?
| Stem Cell Transplantation | 2 | 2003 | 50 |
Why?
| Tumor Cells, Cultured | 12 | 1992 | 233 |
Why?
| Lung Neoplasms | 4 | 1992 | 159 |
Why?
| Whole-Body Irradiation | 4 | 2000 | 43 |
Why?
| Child, Preschool | 16 | 1993 | 554 |
Why?
| Lymphocyte Depletion | 1 | 2005 | 29 |
Why?
| Outpatient Clinics, Hospital | 2 | 1999 | 37 |
Why?
| Mucopolysaccharidosis II | 2 | 2000 | 3 |
Why?
| Male | 26 | 1991 | 1553 |
Why?
| Antibiotic Prophylaxis | 1 | 2003 | 22 |
Why?
| Immunization | 4 | 1986 | 85 |
Why?
| Ethics, Medical | 2 | 2000 | 39 |
Why?
| Opportunistic Infections | 1 | 2003 | 19 |
Why?
| Candida | 1 | 2003 | 19 |
Why?
| Survival Analysis | 3 | 2007 | 205 |
Why?
| Genetic Diseases, Inborn | 2 | 1993 | 13 |
Why?
| Candidiasis | 1 | 2003 | 28 |
Why?
| Antineoplastic Agents | 5 | 1994 | 190 |
Why?
| Simplexvirus | 4 | 1994 | 33 |
Why?
| Mast-Cell Sarcoma | 1 | 2002 | 9 |
Why?
| Severe Combined Immunodeficiency | 5 | 1993 | 9 |
Why?
| Fetal Blood | 3 | 1995 | 54 |
Why?
| Interleukin-6 | 2 | 1992 | 145 |
Why?
| Autoimmune Diseases | 2 | 1994 | 49 |
Why?
| Blood Component Removal | 1 | 2001 | 8 |
Why?
| Fever of Unknown Origin | 2 | 2011 | 5 |
Why?
| Point Mutation | 3 | 1998 | 122 |
Why?
| Clodronic Acid | 1 | 2001 | 12 |
Why?
| Interferon-alpha | 3 | 1999 | 43 |
Why?
| Communicable Diseases | 2 | 2011 | 22 |
Why?
| Antigens, Neoplasm | 2 | 1985 | 56 |
Why?
| Adolescent | 14 | 1993 | 891 |
Why?
| Infant | 12 | 1993 | 464 |
Why?
| Busulfan | 4 | 1999 | 9 |
Why?
| Antigen-Presenting Cells | 1 | 2001 | 40 |
Why?
| Anemia, Hemolytic, Autoimmune | 1 | 2000 | 10 |
Why?
| Leukemia | 1 | 2002 | 70 |
Why?
| Cells, Cultured | 5 | 1992 | 447 |
Why?
| Cytosine Deaminase | 10 | 1992 | 3 |
Why?
| Killer Cells, Natural | 3 | 1986 | 62 |
Why?
| Epitopes | 1 | 2000 | 86 |
Why?
| Hematologic Diseases | 1 | 2000 | 23 |
Why?
| Escherichia coli | 6 | 1992 | 143 |
Why?
| Leukemia, Myeloid, Acute | 2 | 1998 | 53 |
Why?
| Health Resources | 1 | 1999 | 19 |
Why?
| Texas | 3 | 1999 | 21 |
Why?
| Gene Expression Regulation, Viral | 2 | 1994 | 21 |
Why?
| Hospital Costs | 1 | 1999 | 26 |
Why?
| RNA-Binding Proteins | 1 | 2000 | 55 |
Why?
| Joint Diseases | 1 | 1998 | 25 |
Why?
| Necrosis | 1 | 1998 | 82 |
Why?
| Trophoblastic Neoplasms | 1 | 1998 | 3 |
Why?
| Cell Line, Tumor | 2 | 2010 | 208 |
Why?
| Immunosuppressive Agents | 4 | 1996 | 102 |
Why?
| Hematologic Neoplasms | 4 | 1999 | 19 |
Why?
| Influenza Vaccines | 1 | 2000 | 70 |
Why?
| Administration, Oral | 3 | 1999 | 170 |
Why?
| Trophoblasts | 1 | 1998 | 13 |
Why?
| Mice, Inbred Strains | 3 | 1985 | 118 |
Why?
| Retrospective Studies | 8 | 1990 | 653 |
Why?
| Wiskott-Aldrich Syndrome | 2 | 1993 | 6 |
Why?
| Acyltransferases | 1 | 1996 | 6 |
Why?
| Education, Nursing, Continuing | 1 | 1996 | 8 |
Why?
| Histocompatibility | 2 | 2001 | 15 |
Why?
| Nurses | 1 | 1996 | 19 |
Why?
| Leukemia, Experimental | 2 | 2000 | 20 |
Why?
| Transfection | 8 | 1992 | 237 |
Why?
| Disease Progression | 3 | 1996 | 244 |
Why?
| Vaccines, Synthetic | 1 | 1996 | 30 |
Why?
| Ambulatory Surgical Procedures | 1 | 1995 | 12 |
Why?
| Transduction, Genetic | 9 | 1993 | 65 |
Why?
| Flow Cytometry | 2 | 2005 | 216 |
Why?
| Immunocompromised Host | 3 | 1992 | 70 |
Why?
| Mice, Inbred BALB C | 5 | 1995 | 176 |
Why?
| Disease Models, Animal | 3 | 1996 | 349 |
Why?
| Vidarabine | 2 | 2003 | 17 |
Why?
| Clinical Protocols | 4 | 1993 | 93 |
Why?
| Genes, Bacterial | 2 | 1992 | 41 |
Why?
| Personality | 1 | 1996 | 41 |
Why?
| Time Factors | 7 | 1990 | 896 |
Why?
| Injections, Intravenous | 4 | 1999 | 105 |
Why?
| Infusions, Intravenous | 2 | 2001 | 87 |
Why?
| Spleen | 3 | 1985 | 129 |
Why?
| Splenectomy | 1 | 1993 | 29 |
Why?
| HIV Infections | 3 | 1993 | 136 |
Why?
| Antineoplastic Agents, Alkylating | 2 | 2002 | 30 |
Why?
| Risk Assessment | 3 | 1999 | 324 |
Why?
| Protein Conformation | 3 | 1996 | 123 |
Why?
| Informed Consent | 3 | 1999 | 62 |
Why?
| Gastrointestinal Tract | 1 | 2011 | 26 |
Why?
| Treatment Outcome | 3 | 2002 | 661 |
Why?
| Methylprednisolone | 1 | 2011 | 41 |
Why?
| Cell Survival | 3 | 1993 | 229 |
Why?
| Bacterial Proteins | 1 | 1994 | 99 |
Why?
| Prodrugs | 2 | 1998 | 16 |
Why?
| Antibodies, Neoplasm | 1 | 2010 | 28 |
Why?
| Severity of Illness Index | 3 | 2001 | 358 |
Why?
| Patient Discharge | 1 | 1990 | 61 |
Why?
| Clinical Trials as Topic | 3 | 1994 | 251 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2000 | 67 |
Why?
| Glucocorticoids | 1 | 2011 | 107 |
Why?
| Skin Neoplasms | 1 | 1992 | 97 |
Why?
| Phosphoribosylglycinamide Formyltransferase | 3 | 1996 | 1 |
Why?
| Drug Delivery Systems | 1 | 2010 | 55 |
Why?
| Neoplasm Transplantation | 4 | 1986 | 67 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 1998 | 113 |
Why?
| Cell Line | 6 | 1985 | 375 |
Why?
| Antigens, CD34 | 3 | 1993 | 26 |
Why?
| Adult | 10 | 1993 | 1317 |
Why?
| Hematocrit | 1 | 2009 | 60 |
Why?
| Immunotherapy | 2 | 1989 | 48 |
Why?
| Umbilical Veins | 1 | 2009 | 46 |
Why?
| Cyclophosphamide | 3 | 1996 | 82 |
Why?
| Radiation Chimera | 1 | 2008 | 11 |
Why?
| Genes, abl | 1 | 2008 | 5 |
Why?
| Genes, p16 | 1 | 2008 | 10 |
Why?
| Infant, Very Low Birth Weight | 1 | 2009 | 21 |
Why?
| Interferon-gamma | 1 | 2010 | 133 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 135 |
Why?
| Models, Immunological | 1 | 2008 | 40 |
Why?
| Catheterization, Central Venous | 1 | 2009 | 46 |
Why?
| Mice, Transgenic | 2 | 1994 | 209 |
Why?
| Blotting, Western | 1 | 2010 | 275 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2008 | 26 |
Why?
| Gene Expression Profiling | 1 | 2010 | 138 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 243 |
Why?
| Hydrogen-Ion Concentration | 3 | 1996 | 176 |
Why?
| Scattering, Radiation | 2 | 1996 | 36 |
Why?
| Remission Induction | 2 | 2002 | 64 |
Why?
| Communication Barriers | 1 | 2007 | 21 |
Why?
| Language | 1 | 2007 | 23 |
Why?
| Cell Proliferation | 1 | 2010 | 227 |
Why?
| Spectrometry, Fluorescence | 2 | 1996 | 59 |
Why?
| Light | 2 | 1996 | 64 |
Why?
| Follow-Up Studies | 4 | 1993 | 553 |
Why?
| Attitude | 1 | 2007 | 54 |
Why?
| Membrane Proteins | 2 | 2000 | 233 |
Why?
| Liver | 1 | 2011 | 248 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2000 | 210 |
Why?
| Thrombosis | 1 | 2009 | 105 |
Why?
| Melphalan | 1 | 2006 | 24 |
Why?
| Herpes Simplex | 2 | 1994 | 31 |
Why?
| Immunotherapy, Active | 1 | 2005 | 4 |
Why?
| Histocompatibility Antigens | 1 | 2005 | 17 |
Why?
| Blood Cell Count | 2 | 2001 | 31 |
Why?
| Axons | 3 | 1987 | 66 |
Why?
| Comorbidity | 1 | 2007 | 190 |
Why?
| Adenocarcinoma | 4 | 1995 | 167 |
Why?
| Succinimides | 1 | 2005 | 12 |
Why?
| Patient Selection | 1 | 2007 | 155 |
Why?
| Mice, Nude | 4 | 1985 | 72 |
Why?
| Fluoresceins | 1 | 2005 | 50 |
Why?
| Infant, Newborn | 4 | 1994 | 389 |
Why?
| Methylcholanthrene | 2 | 1992 | 7 |
Why?
| Antigens | 1 | 2005 | 66 |
Why?
| Dose-Response Relationship, Drug | 3 | 1991 | 431 |
Why?
| Health Services Accessibility | 1 | 2007 | 72 |
Why?
| Mice, Knockout | 1 | 2008 | 265 |
Why?
| RNA, Messenger | 2 | 2001 | 394 |
Why?
| Prospective Studies | 2 | 1999 | 545 |
Why?
| Hodgkin Disease | 1 | 2006 | 46 |
Why?
| Chediak-Higashi Syndrome | 1 | 2003 | 1 |
Why?
| Fluorescent Dyes | 1 | 2005 | 115 |
Why?
| Hospitalization | 1 | 2007 | 169 |
Why?
| Neoplasms, Radiation-Induced | 1 | 1985 | 31 |
Why?
| Cell Transformation, Neoplastic | 2 | 1985 | 86 |
Why?
| Drug Resistance | 2 | 1996 | 83 |
Why?
| Ischemic Preconditioning | 1 | 2003 | 9 |
Why?
| Azoles | 1 | 2003 | 4 |
Why?
| Glycosyltransferases | 1 | 2003 | 7 |
Why?
| Major Histocompatibility Complex | 1 | 2003 | 23 |
Why?
| Immunodominant Epitopes | 1 | 2003 | 14 |
Why?
| Cell Line, Transformed | 3 | 1996 | 52 |
Why?
| Immunosuppression | 1 | 2003 | 47 |
Why?
| Cord Blood Stem Cell Transplantation | 1 | 2002 | 4 |
Why?
| Peptides | 1 | 2005 | 154 |
Why?
| Drug Administration Schedule | 1 | 2003 | 191 |
Why?
| Risk Factors | 3 | 2001 | 555 |
Why?
| Lymphocytes | 3 | 1995 | 142 |
Why?
| Antifungal Agents | 1 | 2003 | 34 |
Why?
| 3,4-Methylenedioxyamphetamine | 2 | 1991 | 1 |
Why?
| Lorazepam | 1 | 2002 | 11 |
Why?
| Transplantation, Autologous | 5 | 1993 | 78 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 53 |
Why?
| beta-Galactosidase | 1 | 2002 | 63 |
Why?
| Spectrum Analysis | 1 | 2002 | 26 |
Why?
| Molecular Sequence Data | 6 | 1992 | 404 |
Why?
| Antibiotics, Antineoplastic | 1 | 2002 | 35 |
Why?
| Drug Evaluation | 1 | 2002 | 54 |
Why?
| Antimetabolites, Antineoplastic | 2 | 1998 | 29 |
Why?
| Mice, Inbred DBA | 1 | 2002 | 38 |
Why?
| Neurotoxins | 2 | 1991 | 33 |
Why?
| Serotonin | 2 | 1991 | 44 |
Why?
| Cytotoxicity Tests, Immunologic | 2 | 1997 | 23 |
Why?
| Apoptosis | 1 | 2008 | 265 |
Why?
| Fluorouracil | 2 | 1998 | 49 |
Why?
| Candida albicans | 1 | 2003 | 37 |
Why?
| Toxins, Biological | 1 | 2001 | 7 |
Why?
| United States | 4 | 1994 | 604 |
Why?
| Models, Animal | 1 | 2002 | 85 |
Why?
| Blood Bactericidal Activity | 1 | 2001 | 13 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 224 |
Why?
| Bacteremia | 1 | 2001 | 25 |
Why?
| Reference Values | 2 | 1991 | 278 |
Why?
| Peptide Fragments | 1 | 2003 | 144 |
Why?
| Child Welfare | 1 | 2002 | 41 |
Why?
| Anticonvulsants | 1 | 2002 | 61 |
Why?
| Seizures | 1 | 2002 | 79 |
Why?
| Liposomes | 1 | 2001 | 38 |
Why?
| Nucleoproteins | 1 | 2000 | 10 |
Why?
| Canada | 2 | 2011 | 60 |
Why?
| Immunohistochemistry | 4 | 1987 | 355 |
Why?
| Viral Core Proteins | 1 | 2000 | 14 |
Why?
| Combined Modality Therapy | 5 | 1995 | 219 |
Why?
| Coombs' Test | 1 | 2000 | 14 |
Why?
| Iduronate Sulfatase | 1 | 2000 | 2 |
Why?
| Antiviral Agents | 2 | 1997 | 91 |
Why?
| Kanamycin Kinase | 1 | 2000 | 2 |
Why?
| Glycosaminoglycans | 1 | 2000 | 20 |
Why?
| Down-Regulation | 1 | 2002 | 150 |
Why?
| Base Sequence | 5 | 1992 | 371 |
Why?
| Histocompatibility Antigens Class I | 2 | 1989 | 32 |
Why?
| Bromodeoxyuridine | 1 | 2000 | 47 |
Why?
| Antibody Specificity | 1 | 2000 | 71 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2000 | 54 |
Why?
| Ceftazidime | 1 | 1999 | 4 |
Why?
| Adrenal Cortex Hormones | 1 | 2000 | 76 |
Why?
| Episode of Care | 1 | 1999 | 7 |
Why?
| Colonic Neoplasms | 2 | 1996 | 63 |
Why?
| Cancer Care Facilities | 1 | 1999 | 14 |
Why?
| Liver Neoplasms, Experimental | 1 | 1999 | 21 |
Why?
| Gene Products, rev | 1 | 1999 | 4 |
Why?
| Models, Molecular | 2 | 1998 | 102 |
Why?
| Diphtheria Toxin | 1 | 1999 | 13 |
Why?
| Histiocytosis, Non-Langerhans-Cell | 1 | 1998 | 2 |
Why?
| Tacrolimus | 1 | 1999 | 39 |
Why?
| Parents | 1 | 2000 | 89 |
Why?
| Diagnosis, Differential | 1 | 2002 | 402 |
Why?
| Gene Products, tat | 1 | 1999 | 13 |
Why?
| Cephalosporins | 1 | 1999 | 22 |
Why?
| Vaccination | 1 | 2000 | 92 |
Why?
| Spectrophotometry | 1 | 1998 | 53 |
Why?
| Myelodysplastic Syndromes | 1 | 1999 | 27 |
Why?
| Arthritis | 1 | 1998 | 34 |
Why?
| Molecular Weight | 1 | 1998 | 154 |
Why?
| Immunoglobulin G | 1 | 2000 | 191 |
Why?
| Dimerization | 1 | 1998 | 92 |
Why?
| Platelet Count | 2 | 1993 | 39 |
Why?
| Amino Acid Substitution | 1 | 1998 | 68 |
Why?
| Lymphocyte Activation | 2 | 1993 | 137 |
Why?
| Protozoan Proteins | 1 | 1997 | 13 |
Why?
| Test Anxiety Scale | 1 | 1996 | 1 |
Why?
| Age Factors | 1 | 2000 | 480 |
Why?
| Prognosis | 1 | 2000 | 388 |
Why?
| Spectrophotometry, Ultraviolet | 1 | 1996 | 23 |
Why?
| Circular Dichroism | 1 | 1996 | 23 |
Why?
| Histidine | 1 | 1996 | 42 |
Why?
| Genetic Code | 1 | 1996 | 10 |
Why?
| Hydrogen Bonding | 1 | 1996 | 24 |
Why?
| Mutagenesis, Site-Directed | 1 | 1998 | 126 |
Why?
| Dimethylhydrazines | 1 | 1996 | 2 |
Why?
| Protein Structure, Secondary | 1 | 1996 | 54 |
Why?
| T-Lymphocytes, Regulatory | 2 | 1985 | 32 |
Why?
| Macromolecular Substances | 1 | 1996 | 92 |
Why?
| Cloning, Molecular | 2 | 1992 | 183 |
Why?
| Protein Structure, Tertiary | 1 | 1998 | 163 |
Why?
| Clone Cells | 1 | 1996 | 92 |
Why?
| Carcinogens | 1 | 1996 | 40 |
Why?
| Educational Measurement | 1 | 1996 | 60 |
Why?
| Radiation-Sensitizing Agents | 1 | 1996 | 29 |
Why?
| Hemorrhage | 2 | 1993 | 103 |
Why?
| Herpesvirus 3, Human | 1 | 1994 | 14 |
Why?
| Recombinant Fusion Proteins | 3 | 2000 | 189 |
Why?
| Prosencephalon | 2 | 1991 | 29 |
Why?
| DNA, Viral | 1 | 1996 | 98 |
Why?
| Chimera | 1 | 1994 | 22 |
Why?
| Genes, Viral | 1 | 1994 | 37 |
Why?
| Drug Screening Assays, Antitumor | 1 | 1994 | 27 |
Why?
| IMP Dehydrogenase | 1 | 1994 | 9 |
Why?
| Colorectal Neoplasms | 1 | 1996 | 55 |
Why?
| Immunotherapy, Adoptive | 1 | 1993 | 10 |
Why?
| Enhancer Elements, Genetic | 1 | 1994 | 43 |
Why?
| Oncogenes | 1 | 1994 | 24 |
Why?
| Diseases in Twins | 1 | 1993 | 30 |
Why?
| Genes, Tumor Suppressor | 1 | 1994 | 37 |
Why?
| Hematopoietic Stem Cells | 3 | 1993 | 69 |
Why?
| Gene Expression | 2 | 1994 | 291 |
Why?
| Immunity, Innate | 1 | 1994 | 60 |
Why?
| Protein Binding | 1 | 1996 | 256 |
Why?
| HIV-1 | 1 | 1999 | 93 |
Why?
| Recurrence | 2 | 2002 | 261 |
Why?
| Pregnancy | 1 | 1998 | 455 |
Why?
| p-Chloroamphetamine | 1 | 1991 | 1 |
Why?
| Graft Rejection | 1 | 1992 | 59 |
Why?
| Neoplasm Metastasis | 1 | 1992 | 112 |
Why?
| B-Cell Maturation Antigen | 2 | 2000 | 1 |
Why?
| Transmembrane Activator and CAML Interactor Protein | 2 | 2000 | 2 |
Why?
| Injections, Intra-Arterial | 1 | 2011 | 28 |
Why?
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 85 |
Why?
| B-Cell Activating Factor | 2 | 2000 | 8 |
Why?
| Antigens, CD | 1 | 1993 | 128 |
Why?
| DNA Mutational Analysis | 1 | 1992 | 110 |
Why?
| Oligodeoxyribonucleotides | 1 | 1992 | 86 |
Why?
| Leukocytosis | 1 | 1990 | 17 |
Why?
| Promoter Regions, Genetic | 1 | 1994 | 188 |
Why?
| Medical Records | 1 | 2011 | 104 |
Why?
| 3T3 Cells | 2 | 2000 | 54 |
Why?
| Hippocampus | 1 | 1991 | 83 |
Why?
| Leukocyte Count | 1 | 1990 | 94 |
Why?
| Questionnaires | 1 | 1995 | 360 |
Why?
| Phosphorylation | 3 | 1994 | 224 |
Why?
| Cerebral Cortex | 1 | 1991 | 108 |
Why?
| Middle Aged | 2 | 1995 | 1161 |
Why?
| DNA Primers | 2 | 1993 | 208 |
Why?
| Premature Birth | 1 | 2009 | 21 |
Why?
| Gene Expression Regulation | 1 | 1994 | 277 |
Why?
| Locus Coeruleus | 1 | 1987 | 13 |
Why?
| Antibody Formation | 3 | 1986 | 89 |
Why?
| Plasmids | 2 | 1999 | 122 |
Why?
| Spinal Cord | 1 | 1987 | 94 |
Why?
| Stomatitis | 1 | 2006 | 10 |
Why?
| Diarrhea | 1 | 2006 | 41 |
Why?
| Mouth Mucosa | 1 | 2006 | 28 |
Why?
| Blood Transfusion, Autologous | 1 | 1995 | 10 |
Why?
| Immunization, Passive | 1 | 1985 | 39 |
Why?
| Lymphocyte Count | 2 | 1994 | 38 |
Why?
| Rats | 4 | 1987 | 530 |
Why?
| Drug Monitoring | 1 | 2004 | 33 |
Why?
| Brain | 1 | 1992 | 305 |
Why?
| Leukocytes | 1 | 1995 | 94 |
Why?
| Bone Marrow | 1 | 1995 | 109 |
Why?
| Siblings | 1 | 2003 | 28 |
Why?
| Survival Rate | 1 | 2006 | 250 |
Why?
| Ultraviolet Rays | 1 | 1985 | 76 |
Why?
| Sleep Stages | 1 | 2002 | 16 |
Why?
| Daunorubicin | 1 | 2002 | 10 |
Why?
| Metabolic Clearance Rate | 1 | 2002 | 31 |
Why?
| Case-Control Studies | 1 | 2004 | 283 |
Why?
| Biological Transport | 2 | 1987 | 129 |
Why?
| Drug Interactions | 1 | 2002 | 111 |
Why?
| B-Cell Activation Factor Receptor | 1 | 2001 | 1 |
Why?
| Mice, Inbred A | 1 | 2001 | 15 |
Why?
| Chromosomes, Human, Pair 22 | 1 | 2001 | 12 |
Why?
| Likelihood Functions | 1 | 2001 | 43 |
Why?
| Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2000 | 1 |
Why?
| HT29 Cells | 1 | 2000 | 3 |
Why?
| Lymphoid Tissue | 1 | 2001 | 34 |
Why?
| Solubility | 1 | 2000 | 75 |
Why?
| Chromosome Mapping | 1 | 2001 | 107 |
Why?
| Homeostasis | 1 | 2001 | 99 |
Why?
| Ligands | 1 | 2001 | 116 |
Why?
| Thiotepa | 1 | 1999 | 6 |
Why?
| Histocompatibility Testing | 1 | 1999 | 24 |
Why?
| Recombinant Proteins | 1 | 2002 | 290 |
Why?
| rev Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 3 |
Why?
| Methotrexate | 1 | 1999 | 40 |
Why?
| HIV Core Protein p24 | 1 | 1999 | 17 |
Why?
| Tissue Donors | 1 | 1999 | 41 |
Why?
| Blotting, Southern | 1 | 1999 | 69 |
Why?
| Prenatal Diagnosis | 1 | 1999 | 31 |
Why?
| Coenzymes | 1 | 1998 | 16 |
Why?
| Aging | 1 | 1985 | 275 |
Why?
| Hematopoiesis | 1 | 1999 | 47 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 1 | 1999 | 15 |
Why?
| Leukopoiesis | 1 | 1998 | 6 |
Why?
| Culture Media, Conditioned | 1 | 1998 | 45 |
Why?
| Antigens, CD45 | 1 | 1998 | 30 |
Why?
| Phosphotransferases | 1 | 1998 | 24 |
Why?
| Regeneration | 1 | 1998 | 27 |
Why?
| Blotting, Northern | 1 | 1999 | 151 |
Why?
| Crystallography, X-Ray | 1 | 1998 | 41 |
Why?
| Cell Division | 1 | 2000 | 273 |
Why?
| Disease-Free Survival | 1 | 1998 | 102 |
Why?
| Bone Marrow Cells | 1 | 1999 | 92 |
Why?
| Amino Acid Sequence | 1 | 2001 | 319 |
Why?
| Immunomagnetic Separation | 1 | 1997 | 6 |
Why?
| Antigens, Protozoan | 1 | 1997 | 6 |
Why?
| Plasmodium falciparum | 1 | 1997 | 9 |
Why?
| Cell Transformation, Viral | 1 | 1997 | 35 |
Why?
| Coculture Techniques | 1 | 1997 | 59 |
Why?
| Carrier Proteins | 1 | 2000 | 177 |
Why?
| Polymerase Chain Reaction | 1 | 1999 | 279 |
Why?
| Binding Sites | 1 | 1998 | 213 |
Why?
| Transcription, Genetic | 1 | 2000 | 253 |
Why?
| Immunity, Cellular | 1 | 1995 | 85 |
Why?
| X Chromosome | 1 | 1994 | 24 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 1997 | 91 |
Why?
| Kinetics | 1 | 1998 | 349 |
Why?
| Immunoglobulins, Intravenous | 1 | 1994 | 32 |
Why?
| Chloramphenicol O-Acetyltransferase | 1 | 1994 | 21 |
Why?
| Thymine Nucleotides | 1 | 1994 | 8 |
Why?
| Genetic Linkage | 1 | 1994 | 57 |
Why?
| Immunologic Memory | 1 | 1995 | 51 |
Why?
| Aminohydrolases | 1 | 1993 | 3 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 48 |
Why?
| Ribavirin | 1 | 1994 | 23 |
Why?
| HIV Seronegativity | 1 | 1993 | 13 |
Why?
| Twins, Monozygotic | 1 | 1993 | 28 |
Why?
| HeLa Cells | 1 | 1994 | 107 |
Why?
| Safety | 1 | 1993 | 80 |
Why?
| Feasibility Studies | 1 | 1993 | 144 |
Why?
| Designer Drugs | 1 | 1992 | 1 |
Why?
| Isomerism | 1 | 1992 | 24 |
Why?
| Macaca mulatta | 1 | 1993 | 71 |
Why?
| Signal Transduction | 1 | 2001 | 313 |
Why?
| Phenotype | 1 | 1994 | 303 |
Why?
| DNA | 1 | 1997 | 262 |
Why?
| Organ Specificity | 1 | 1991 | 104 |
Why?
| Rats, Inbred Strains | 1 | 1991 | 170 |
Why?
| Dopamine beta-Hydroxylase | 1 | 1987 | 8 |
Why?
| Phytohemagglutinins | 1 | 1987 | 25 |
Why?
| Hemolytic Plaque Technique | 1 | 1986 | 6 |
Why?
| Poly I-C | 1 | 1986 | 7 |
Why?
| Interferons | 1 | 1986 | 39 |
Why?
| Immunoglobulin M | 1 | 1986 | 81 |
Why?
|
|
Mullen's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
